Safety and Efficacy of Post-marketing Transcatheter Aortic Valves in "Real World" Chinese Patients

Recruiting now

Conditions studied: Aortic Valve Disease Mixed

In brief

The purpose of this prospective multi-center, observational registry in China is to collect clinical baseline, procedural, and follow-up data of all patients treated with TAVR in China and to evaluate short-, mid-, and long-term clinical outcome data of all post-marketing transcatheter valves. Each center will collect baseline and procedural data as well as clinical outcomes for up to 10 years.

Key facts

Study ID

NCT06257043

Run by

Xijing Hospital

People needed

3000

Starts

2023-10-30

Expected to finish

2034-01-01

Last updated by the study team

2024-04-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with aortic valve disease are evaluated by the cardiac team and indicate TAVR therapy
• Patients who understand the purpose of this study, voluntarily participate in the trial and sign the informed consent form

You may not qualify if…

• Patients with aortic valve disease who have been evaluated by a cardiac team as unsuitable for TAVR
• Patients who cannot tolerate the materials or medications associated with this study
• Women who are pregnant or breastfeeding
• Patients who participated in a clinical trial of another drug or medical device before enrollment

Where it is running

• Ling Tao — Xi'an, Shaanxi, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.